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Background: Papillary thyroid carcinoma (PTC) is themost common and less aggressive
thyroid cancer, but some patients may display locally advanced disease. Therapeutic
options are limited in these cases, particularly for those patients with unresectable
tumors. Neoadjuvant therapy is not part of the recommended work up.
Methods: Report a case of an unresectable grossly locally invasive PTC successfully
managed with neoadjuvant therapy and provide a systematic review (SR) using the terms
“Neoadjuvant therapy” AND “Thyroid carcinoma.”
Results: A 32-year-old man with a 7.8 cm (in the largest dimension) PTC was referred
to total thyroidectomy, but tumor resection was not feasible due to extensive local
invasion (trachea, esophagus, and adjacent structures). Sorafenib, a multikinase inhibitor
(MKI), was initiated; a 70% tumor reduction was observed after 6 months, allowing new
surgical intervention and complete resection. Radioactive iodine (RAI) was administered
as adjuvant therapy, and whole body scan (WBS) shows uptake on thyroid bed.
One-year post-surgery the patient is asymptomatic with a status of disease defined as an
incomplete biochemical response. The SR retrieved 123 studies on neoadjuvant therapy
use in thyroid carcinoma; of them, 6 were extracted: 4 case reports and 2 observational
studies. MKIs were used as neoadjuvant therapy in three clinical cases with 70–84% of
tumor reduction allowing surgery.
Conclusion: Our findings, along with other reports, suggest that MKIs is an effective
neoadjuvant therapy and should be considered as a therapeutic strategy for unresectable
grossly locally invasive thyroid carcinomas.
Keywords: thyroid carcinoma, multikinase inhibitors, neoadjuvant therapy, unresectable thyroid tumors, locally
invasive thyroid tumors
INTRODUCTION
Thyroid carcinoma is the most common endocrine malignancy, accounting for 3.1% of the global
incidence of cancers in 2018 (1). Differentiated thyroid carcinoma (DTC), including papillary
(PTC) and follicular carcinoma (FTC), is derived from follicular cells of the thyroid gland and
accounts for the majority of thyroid malignancies. Approximately 84% of DTC tumors are PTC,
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affecting mainly female patients aged 40–59 years (2, 3). PTC
is usually an indolent tumor, with an excellent prognosis.
The initial therapeutic approach to DTC consists of total
thyroidectomy, which might be followed by radioactive iodine
(RAI) administration, and TSH suppression in selected cases (4–
6). The incidence of unresectable PTC is unknown, and for these
patients, therapeutic options are limited and disappointing.
Multikinase inhibitors (MKI) are drugs indicated for bulky
or rapidly progressing iodine-refractory metastatic DTC, that
result in symptomatic or threatening uncontrolled disease not
amenable to other therapies (4). The antiproliferative MKI effect
has been demonstrated in primary papillary dedifferentiated
thyroid cancer (DePTC) cells whereas potent inhibition of
angiogenesesis and growth were shown in nude mice bearing
thyroid tumor xenografts (7, 8). The antitumor effects were
confirmed in clinical studies, and currently, twoMKI compounds
have been approved by the Food andDrug Administration (FDA)
for iodine-refractory PTC treatment: sorafenib and lenvatinib
(9, 10). Sorafenib inhibits VEGFR-1, VEGFR-2 and VEGFR-
3, RET (including RET/PTC), RAF (including BRAF V600E),
and platelet-derived growth factor B receptor. In the DECISION
trial, the benefits of sorafenib were evidenced by higher rates
of progression-free survival (PFS): 10.8 vs. 5.8 months, P <
0.0001. The best response in tumor reduction reached 60%, but
no benefit for overall survival was documented (9). Lenvatinib,
the second MKI approved, inhibits VEGFRs 1,2, and 3, FGFRs
1,2,3, and 4; PDGFR α, RET, and KIT signaling networks. The
SELECT trial showed that patients with locally advanced disease
in the lenvatinib group, even those that received another MKI
before randomization, achieved a PFS benefit. The median PFS
was 18.3 months in the lenvatinib group vs. 3.6 months in
the placebo group (HR for progression or death, 0.21; 99%
confidence interval, 0.14–0.31; P < 0.001). Lenvatinib achieved
the best response rate of 64.8% (4 complete responses) vs. 1.5%
in the placebo group (P < 0.001) (10).
Neoadjuvant therapy refers to the administration of
therapeutic agents before a primary treatment, usually surgery,
aiming to reduce the size of the tumor (11). The use of MKI
as neoadjuvant therapy is a well-established therapeutic tool
for several human neoplasias (12–14). However, neoadjuvant
treatment is an unusual event in the management of thyroid
carcinoma. Indeed, it is not mentioned in the current DTC
guidelines (4–6). Here, we report a patient presenting with
locally advanced unresectable PTC who displayed a 70% tumor
reduction after neoadjuvant treatment with sorafenib, allowing
complete surgical resection. Additionally, a systematic review of
neoadjuvant therapies for thyroid carcinoma is provided.
CASE REPORT
Clinical Presentation and Management
A 32-year-old man presented with a cervical lesion of 7.8 cm (in
the largest diameter), which was diagnosed as classical PTC by
fine needle aspiration (FNA) cytology analysis and was referred
to total thyroidectomy. However, the complete tumor resection
was not feasible due to the invasion of trachea, esophagus and
adjacent structures, the absence of a clear cleavage plane, along
with compression, of cervical vessels, and only a partial resection
of the left lobe of the thyroid was performed. The surgical
product sent for histopathological examination showed a classical
PTC with complex branching randomly oriented papillae with
fibrovascular cores lined by cuboidal neoplastic cells. Carcinoma
cell nuclei overlapped and showed finely dispersed optically clear
chromatin (Figures 1A–D).
Immediate postoperative computed tomography (CT)
displayed a lesion measuring 6.8 × 3.4 × 3.4 cm (Figure 2A) in
contact with the carotid space, infiltrating the fat surrounding
the vascular structures, with lateral deviation and reduction of
the caliber of the internal jugular vein and no cleavage plan with
the cervical musculature. Atypical lymph nodes on the left side of
the neck up to 1.0 × 1.0 × 1.0 cm in diameter and three nodular
lung opacities of 0.6, 0.4, and 0.4 cm diameters, considered
non-specific, but suspicious for PTC metastasis were described.
Due to the advanced unresectable disease, neoadjuvant
therapy with sorafenib (800mg per day) was started, aiming to
reduce the lesion to allow surgical treatment. During sorafenib
use, the patient presented hypertension, and grade II hand-foot
syndrome both controlled with oral medications and topical
measures. After 6 months of treatment, the large cervical lesion
showed a reduction of 70% of the largest diameter from baseline
(2.0 × 1.9 × 1.6 cm—Figure 2B) in CT, defined as a partial
response by RECIST criteria (15). Now, the lesion showed a
cleavage plane with adjacent structures and cervical vessels.
Sorafenib was stopped and surgery scheduled for 30 days later.
A new CT immediately before surgery documented stable disease
(target lesion size: 2.3× 2.2× 1.9 cm).
The patient underwent a new surgical procedure, and the
entire macroscopic PTC lesion was resected together with four
cervical lymph nodes of the left jugular chain and mediastinal
fat. Cervical vessels was preserved, but it was necessary to
shave the trachea and esophagus and resect the left recurrent
laryngeal nerve. The postoperative course was unremarkable,
with no need for tracheostomy or ventilatory support, and the
patient was discharged home on the third postoperative day.
The histopathological analysis demonstrated a 2.5 cm classical
PTC and another focus spanning 0.5 cm on the left lobe. Also,
a 0.2 cm focus of PTC as identified in adipose tissue, 3 left jugular
metastatic lymph nodes and positive surgical margins (pT4a
N1b Mx—stage I). Compared to the pre neoadjuvant specimen,
residual papillae were fibrotic and extensive areas of stromal
fibrosis showing old hemorrhage and foreign body inflammation
were observed (Figures 1E–H).
One month after surgery the patient received RAI therapy
(100 mCi) administered in a stimulated TSH condition of
endogenous hypothyroidism after withdrawing levothyroxine
for 4 weeks (TSH 89.8 µUI/mL; normal reference: 0.27–
4.2 µUI/mL). Serum thyroglobulin (Tg) showed a value
of 42.6 ng/mL (sensibility < 0.1 ng/mL) with positive anti-
thyroglobulin antibody (AAT) (6.4 UI/mL; reference < 4.11
UI/mL). A post-therapy whole body scan (WBS) was performed
10 days after the radioiodine administration, showing uptake
at the thyroid bed. The disease status after 1 year of follow-up
is an incomplete biochemical response (TSH: 9.1 µUI/mL; Tg:
5.2 ng/mL; AAT: 5.3 UI/mL and imaging exams without evidence
of suspicious lesions). A written informed consent was obtained
from the patient for the publication of this case report.
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FIGURE 1 | Pre (A–D) and post-neoadjuvant (E–H) histopathological analysis of the classical papillary thyroid carcinoma surgical specimens. (A,B) Complex,
branching, randomly oriented papillae with fibrovascular areas (HE 100X); (C,D) papillae lined by cuboidal cells, nuclei overlap with finely dispersed optically clear
chromatin (HE 400X); (E) papillae showing fibrotic fibrovascular areas (HE 400X); (F) preserved neoplastic architecture (HE 400X); (G) foreign body granuloma (HE
100X); (H) densely fibrotic area showing old hemorrhage and residual infiltrative carcinoma (HE 100 X). Expression of VEGF, VEGFR-1, VEGFR2, and CD31
immunolabeling in pre (I–L) and post-neoadjuvant (M–P) surgical specimens, respectively. (I) light positivity in tumor cells and vascular endothelium; (J) highlighted a
prominent vascular network in the neoplastic papillae; (K) negative staining; (L) intense staining in tumor cells maintained; (M,O) slightly increased positivity in tumor
cells; (P) intense staining in tumor cells; (N) reduction in number and the caliber of vessels within fibrovascular areas (all 400X).
Tumor Markers and Genetic Analysis
Additionally to hematoxylin and eosin staining,
immunohistochemistry analysis (IHC) was performed on
thin sections (3µm) of previously formalin-fixed and paraffin-
embedded tissues. Expression of VEGF, VEGFR-1, VEGFR2, and
CD31 immunolabeling was assessed in pre and post-neoadjuvant
surgical specimens (Figures 1I–L). The immunoreactivity was
scored as negative (–) absence of labeling; (+) discrete intensity;
(++) moderate intensity; and (+++) accentuated intensity. Pre
and post-treatment surgical specimens were compared, and the
VEGF and VEGFR 1 displayed slightly increased positivity in
tumor cells. On the other hand, a reduction in the number and
caliber of vessels within fibrovascular cores when analyzing the
CD31 antibody was observed (Figures 1M–P).
Molecular DNA analysis was performed in paraffin-embedded
tumor tissue using the Magnesil Genomic Fixed Tissue System
(Promega, Madison, WI, USA), according to the manufacturer’s
instructions Pointmutations at codon 600 of BRAF and at codons
12, 13, and 61 of K-, H-, and N-RASwere evaluated by PCR using
specific primers and submitted to direct sequencing by standard
procedures previously described (16). No known mutation was
found in the analyzed exons and isoforms of the RAS gene. The
BRAF V600E mutation was also negative.
SYSTEMATIC REVIEW
Methods
The electronic databases PubMed/Medline and Embase were
searched for studies of neoadjuvant therapy for thyroid
carcinoma. The reference lists of all identified articles were
examined, and authors of included studies were consulted to
obtain additional information when needed.
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FIGURE 2 | Thyroid CT scans pre (A) and after 6 months (B) of neoadjuvant
sorafenib therapy.
Two investigators (CFN and RSS), blinded to each other’s
rating, independently assessed study eligibility. All data were
independently abstracted in duplicate using a standardized
abstraction form. Differences in data extraction were resolved by
a third party (JMD) and by referencing the original publication.
A search using the terms “Neoadjuvant therapy” AND
“Thyroid carcinoma,” with a language filter for articles in English
on August 14th, 2018 retrieved 123 articles. Four manuscripts
were excluded due to duplicated data. Based on title and abstract
content, 88 studies were excluded because they did not include
thyroid tumors, 15 because of lack of data from neoadjuvant
therapy, 7 because they included thyroid tumors other than DTC
or medullary thyroid carcinoma (MTC), 1 was not performed
in humans, 1 was written in another language than English
(French), and 1 review article. After the inclusion of the present
case, a total of 5 case reports and 2 observational studies
were included (Figure 3). A summarized description of the
characteristics of the studies is shown in Table 1.
This systematic review was planned and reported according
to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement guidelines (17).
RESULTS
Chemotherapy
Two retrospective studies of neoadjuvant chemotherapy for
patients with DTC considered inoperable were identified
(18, 19). Treatment regimens consisted mostly of vinblastine,
vinblastine plus adriamycin or other regimens in the two
studies. Four follicular thyroid carcinomas (FTC) of 16 patients
additionally received radiotherapy due to tumor progression
despite chemotherapy and before surgery. Treatment response
results were similar between PTC and FTC populations: 13/29
(45%) and 7/16 (44%) of patients with a tumor reduction of more
than 50%, respectively. All patients underwent surgery, allowing
a total or near total thyroidectomy in 24/29 (83%) and 11/16
(69%). After surgery, radioiodine was administered to 26/29
(90%) and 14/16 (87%); and radiotherapy to 20/29 (69%) and
12/16 (75%), respectively. In the follow-up 4/29 (14%) and 2/16
(13%) patients were disease-free; 2/29 (7%) and 4/16 (25%) had
persistent disease and 17/29 (59%) and 8/16 (50%) died from the
disease, respectively. Mean disease-free survival was 110 months
(7–201) for PTC and 110 months (5–218) for FTC patients.
Radioiodine
We identified one case report on the use of RAI as neoadjuvant
therapy for PTC. A 57-year-old woman, with inoperable PTC,
tumor size of 6.0 cm with symptoms of hoarseness and dyspnea.
the patient received 3 doses of RAI from March 1995 to
November 1996, with a cumulative radioiodine activity of 270
mCi. At this time, the tumor diameter was 3.0 cm, and total
thyroidectomy was performed 30 days after the last RAI dosing;
the patient was followed up for 1 year, but the final disease status
was not reported (20).
Multikinase Inhibitors
Three previous case reports of neoadjuvant MKI for thyroid
carcinoma were identified. The first report describes a 45-
year-old woman with suspected anaplastic thyroid carcinoma
who initially received radiotherapy and chemotherapy (cisplatin
and doxorubicin) for 5 weeks. As no response was observed,
the chemotherapy was shifted to carboplatin and paclitaxel
for 2 weeks, still in association with radiotherapy. Due to the
absence of response, sunitinib 50mg daily was initiated in an
intermittent schedule (4 weeks on and 2 weeks off medication).
Total thyroidectomy was performed after 19 months of therapy
when the tumor was considered potentially resectable. The
histopathological analysis revealed MTC (21).
The second case was a 73-year-old man with a locally
advanced PTC for whom surgery was considered highly invasive.
He received lenvatinib 14 mg/day for 18 weeks, resulting in a
primary tumor reduction of 84%, along with a 56% reduction
of cervical lymph nodes metastases. Total thyroidectomy was
then performed, preserving the patient’s esophagus. The patient
received radioiodine and did not present evidence of distant
metastases at 10 months follow-up after surgery (22).
The third report was a 20-year-old man with symptomatic
PTC. Surgery was attempted but was stopped due to
transoperative profuse tumor bleeding. At that time, sorafenib
800mg daily was started and maintained for 13 months. The
tumor displayed a significant reduction, which allowed surgery.
Due to the tracheal invasion, the patient underwent cervical
external beam radiotherapy and radioiodine dosing (the total
activity of 300 mCi). At 52 months of follow-up, the patient has
stable, persistent structural disease (23).
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FIGURE 3 | Flow diagram of reference identification and selection.
DISCUSSION
PTC is usually an indolent tumor with an excellent prognosis.
However, a small but significant percentage of patients
with thyroid carcinomas may have locally advanced
disease at initial presentation. Differentiated thyroid cancer
(DTC) with Invasion of surrounding structures can lead
to morbid procedures such as laryngectomy and tracheal
resection. Invasion of trachea or larynx occur in 3.6–
22.9% of thyroid cancer patients and advanced airway
invasion with endoluminal tracheal involvement occurs
in 0.5–1.5% of cases (24–26). Due to the disappointing
results obtained with previous chemotherapy strategies, the
current DTC guidelines do not recommend neoadjuvant
therapy for patients with unresectable in whom surgery
is contraindicated (4).
Indeed, a systematic literature search identified only
two observational, retrospective studies of neoadjuvant
chemotherapy for patients with inoperable thyroid
carcinomas, both from the same Slovenian group (18, 19).
Of note, 71% (n = 32/45) of these patients required
complementary RAI administration, and there is no
report on the side effects. These findings limit the
inferences about the risk/benefit balance of neoadjuvant
chemotherapy for thyroid carcinoma. RAI administration
was used as neoadvujant therapy in one case report, which
limits conclusions.
MKI has only recently emerged as an alternative
treatment for refractory-DTC thyroid cancer. However, it
has rarely considered as a potential neoadjuvant therapy
strategy for thyroid cancer. Here, we describe a case of
a young male patient with unresectable grossly locally
invasive PTC successfully managed with MKI neoadjuvant
therapy. After MKI therapy, the patient underwent surgical
resection and RAI administration and currently presents
an incomplete biochemical status. A literature search



































TABLE 1 | Publications retrieved from the search in database on neoadjuvant therapy and thyroid carcinoma.










Neoadjuvant therapy Response to therapy Surgery Disease status
Besic et al. Slovenia/2012 Retrospective/
Follicular or
Hurthle cell
29 61 Vinblastine (19 patients);
vinblastine + adriamycin (5
patients); or other ChT (5
patients)
45% patients with >50%
tumor reduction
15 patients no residual tumor; 10
patients microscopic residual
tumor; and 4 patients
macroscopic residual tumor
4 excellent response
2 with persistent disease
17 deaths from the disease and
6 deaths from other causes
Besic et al. Slovenia/2013 Retrospective/PTC
and variants*
16 63 Vinblastine (11 patients);
vinblastine + adriamycin (2
patients); or other ChT (3
patients). Of note, 4 patients
received neoadjuvant RhT due to
tumor progression
44% patients with >50%
tumor reduction
2 patients no residual tumor; 10
patients microscopic residual
tumor; and 4 patients
macroscopic residual tumor
2 excellent response
4 with persistent disease
8 deaths from the disease
Shingu et al. Japan/1998 Case
report/PTC
1 57 RAI (180 mCI) 50% of tumor reduction Total thyroidectomy, partial
resection of trachea, bilateral
modified neck dissection, and
upper mediastinal dissection
Alive for 1 year
Cleary et al. USA/2010 Case
report/MTC
1 45 RhT + Cisplatin plus adriamycin
after carboplatin plus placlitaxel
and last sunitinib for 19
Tumor reduction allowing
surgical resection
Total thyroidectomy, resection of
the mediastinal mass, and a
central compartment and left
neck dissection
Alive; calcitonin 106 pg/mL,
without evidence of macroscopic
disease
Multikinase Inhibitors as Neoadjuvant Therapy
Tsuboi et al. Japan/2017 Case
report/PTC
1 73 Lenvatinib for 18 weeks 84% of tumor reduction Total thyroidectomy, modified
neck dissection, resection of the
muscular layer of the esophagus,
and a tracheal sleeve resection
and reconstruction
Alive without distant metastases
Danilovic et al. Brazil/2018 Case
report/PTC
1 20 Sorafenib for 13 months Tumor reduction that
allowed surgical therapy
Near total thyroidectomy and
bilateral neck dissection
Structural incomplete response
Nava et al. Brazil/2019 Case
report/PTC
1 32 Sorafenib for 6 months 70% tumor reduction Total thyroidectomy, left jugular




ChT, chemotherapy; RhT, radiotherapy; PTC, papillary thyroid carcinoma; MTC, medullary thyroid carcinoma; RAI, radioiodine therapy; NA, not available; *poorly differentiated PTC; Classical PTC; Follicular variant of PTC; and Hurthle
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showed the use of MKI as neoadjuvant therapy for locally
advanced DTC in 4 case reports; Tumor reduction was
observed in all cases, allowing posterior surgery, three of
them with complete resection. These data point out MKIs
as an effective and feasible alternative for unresectable
locally advanced thyroid tumors, potentially changing
the course of the disease in those patients with advanced
local disease.
An original aspect of this study was the opportunity
to evaluate the histopathological changes secondary to
MKI therapy in a PTC specimen. Gross pathological
examination showed a significant reduction in the tumor
size while microscopic examination revealed a fibrotic and
hemorrhagic residual tumor. Changes in VEGF and VEGFR
immunohistochemical staining, together with decreases of the
CD31-positive intratumoral vascular network, corroborate
the powerful antiangiogenic and antiproliferative effect
of sorafenib on thyroid tumor cells. Of interest, Yuen
et al. described similar findings in a renal cell carcinoma
xenograft model where sorafenib-treated mice showed
reduced mean percentage of CD-31-positive endothelial
cells (27).
In summary, the use of MKI neoadjuvant therapy
is particularly beneficial for locally advanced thyroid
carcinomas. Our observations shed light on new
treatment strategies, which can potentially minimize
morbidity, improving disease status and long-term
prognosis in a subgroup of patients with locally aggressive
thyroid carcinoma.
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